Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 2, 2008 Brian Orelli	Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool October 14, 2008 Brian Orelli	Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool December 22, 2009 Brian Orelli	This Acquisition Is Icy Hot Expensive price, but Chattem may still be a good buy for sanofi-aventis.
The Motley Fool April 16, 2008 Brian Orelli	Johnson & Johnson Chugs Along Strong growth, mostly from the weak dollar, fails to excite Johnson & Johnson's investors.
The Motley Fool March 31, 2011 Brian Orelli	Johnson & Johnson Hires a Babysitter J&J tries to turn the OTC business around; the McNeil Consumer Health care unit will now be headed up by Patrick Mutchler, previously the head of the health-care giant's baby products..
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool March 11, 2011 Brian Orelli	Johnson & Johnson Gets a Slap on the Wrist The consent decree could have been a lot worse.
The Motley Fool November 26, 2010 Brian Orelli	Get It Together, Johnson & Johnson Another day, another recall.
The Motley Fool February 22, 2010 Brian Orelli	A Huge Business Wrapped Up in Tiny Packages Drug investors shouldn't forget about over-the-counter products.
The Motley Fool August 4, 2011 Brian Orelli	Pfizer's Long-Shot Lipitor Gamble Don't count on OTC Lipitor anytime soon.
The Motley Fool December 31, 2009 Brian Orelli	The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool January 15, 2010 Brian Orelli	The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem.
The Motley Fool November 2, 2011 Brian Orelli	Lipitor Loss Looming, Pfizer Shines Good thing it's already priced in.
The Motley Fool August 28, 2007 Brian Orelli	A Combination to Clear Your Head Merck and Schering-Plough get together again. But who can blame them? Their partnerships have been making both companies lots of money. Investors, take note.
The Motley Fool May 29, 2009 Brian Orelli	Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales.
The Motley Fool October 7, 2010 Anders Bylund	Affymax Shares Plunged: What You Need to Know Affymax plunged as much as 11.6% in early trading today after an unfavorable ruling in a patent dispute with larger drug developer Johnson & Johnson.
The Motley Fool January 26, 2010 Brian Orelli	Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool July 28, 2011 Melly Alazraki	J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.
The Motley Fool March 25, 2011 Brian Orelli	Teva:P&G :: Peanut Butter:Chocolate The generic-drug maker and consumer-products company are forming a joint venture to sell over-the-counter medication, with both companies bringing their strengths to the table.
The Motley Fool December 14, 2007 Brian Orelli	Panel Kills Merck's Hope of OTC Status An FDA advisory panel isn't convinced that Merck's cholesterol-lowering drug MEVACOR deserves OTC status.
The Motley Fool July 8, 2011 Brian Orelli	Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block.
The Motley Fool February 22, 2010 Brian Orelli	So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool October 19, 2010 Brian Orelli	Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings.
The Motley Fool May 28, 2008 Brian Lawler	No Barrier to Deals Like This In the latest example of overlap between the pharmaceutical and consumer-health care industries, Barrier Therapeutics announces that it will package one of its lead prescription drugs with a shampoo sold by Procter & Gamble.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool July 16, 2008 Brian Orelli	J&J's Lesson to Investors: Diversify! Johnson & Johnson's second-quarter earnings report gives investors an object lesson of the benefits of the principle of diversification.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool February 11, 2009 Brian Orelli	The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder.
The Motley Fool April 27, 2009 Brian Orelli	Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
The Motley Fool August 29, 2011 Brian Orelli	A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER.
The Motley Fool January 20, 2009 Brian Orelli	Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
The Motley Fool July 9, 2010 Brian Orelli	Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products.
The Motley Fool March 17, 2009 Brian Orelli	Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace.
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
Reason Aug/Sep 2001 Jacob Sullum	Through the Nose An FDA advisory committee has voted overwhelmingly to recommend over-the-counter status for Claritin, Allegra, and Zyrtec, three popular prescription allergy drugs. But the drugs' manufacturers are opposing a switch, fearing that it could hurt their profits...
The Motley Fool April 26, 2011 Brian Orelli	We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants.